SCHEMBL5060733

SCHEMBL5060733

O=C(O)c1ccccc1NC(=O)N1CCN(Cc2ccccc2OCc2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 9/20 0.57
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 3/20 0.51
ALOX15 P16050 2/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CA12 O43570 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
HTT P42858 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 1/20 0.47
HCAR2 Q8TDS4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603238 0.87 FAAH (0.70) FAAHKDM4ECA12CA2CA9
SCHEMBL16673662 0.81 KDM4E (0.58) FAAHKDM4EALDH1A1ALOX15LMNA
SCHEMBL5055479 0.78 FAAH (0.71) FAAHKDM4EALDH1A1ALOX15USP2
SCHEMBL5056797 0.77 FAAH (0.53) FAAHKDM4EALDH1A1ALOX15USP2
SCHEMBL5062709 0.77 FAAH (0.72) FAAHKDM4EALDH1A1ALOX15USP2
SCHEMBL5060754 0.75 FAAH (0.53) FAAHKDM4EALDH1A1ALOX15USP2
SCHEMBL5055244 0.75 KMT2A (0.74) FAAHKDM4EALDH1A1ALOX15USP2
SCHEMBL5060796 0.73 FAAH (0.56) FAAHKDM4EALDH1A1ALOX15USP2
SCHEMBL3609507 0.73 FAAH (1.00) FAAH
SCHEMBL12509224 0.72 MAPT (0.53) FAAHLMNAMAPTHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia SMITHKLINE BEECHAM CORPORATION 2008-06-12 US claimed
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia SMITHKLINE BEECHAM CORPORATION 2008-06-12 US disclosed
EP-1848707-A1 AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA SMITHKLINE BEECHAM CORPORATION (US) 2007-10-31 EP disclosed
WO-2006085108-A1 AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA SMITHKLINE BEECHAM CORPORATION (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia ANTXR2, CYP46A1, HCAR1 FAAH 361/4885KDM4E 3897/4885ALDH1A1 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.